30.06.2025

Alithea Bio at #BayOConnect2025: Let’s Shape the Future of Immunotherapy

bayoconnect 2025 AlitheaBio

We’re excited to announce that Alithea Bio will be attending #BayOConnect2025 in Munich on 1–2 July 2025.

We’re excited to announce that Alithea Bio will be attending BayOConnect in Munich on 1–2 July 2025.

Our Chief Scientific Officer, Dr. Tim Fugmann, will be taking the stage on 2 July 2025, between 11:30 AM and 12:30 PM, to share insights into our cutting-edge work in immunotherapy.

📍 Schedule a meeting with us to discuss

  • Navigating peptide presentation with HLA-Compass

  • Discovering and validating target (neo)epitopes

  • Predicting off-target toxicity

  • Exploring our HLA-typed biorepository

If you’re attending the conference, we’d love to connect and explore how Alithea Bio can support your goals in immunotherapy, cancer research, and HLA-peptidomics.

Let’s shape the future of precision medicine together.

Read more

7th-TCR-Based-Therapies-Summit-logo-1-scaled-1.webp Aliteha bio

Alithea Bio to Join Industry Leaders at the 7th TCR-Based Therapies Summit in Boston

Read
Alisa Fuchs, PhD, German Innovation Award 2026

Alithea Bio Receives German Innovation Award 2026 for HLA-Compass Platform

Read
HLA binding prediction tool HLA-Compass AI Alithea Bio deep learning immunopeptidomics

HLA Binding Prediction: How Alithea Bio Outperforms MHCflurry 2.0

Read